Avenzo Therapeutics, Inc.
Clinical trials sponsored by Avenzo Therapeutics, Inc., explained in plain language.
-
New pill shows promise against Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new oral drug called AVZO-023 in people with advanced solid tumors, including a type of breast cancer (HR+/HER2-). The goal is to find a safe dose and see if it can shrink tumors. About 380 adults will take the drug alone or with other treatments.
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 00:32 UTC
-
New drug AVZO-103 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis study tests a new drug called AVZO-103 in people with advanced bladder cancer or other solid tumors that have spread. The drug is designed to attack cancer cells directly. The main goals are to find a safe dose and see if it shrinks tumors. About 355 adults will take part.
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 00:29 UTC
-
New pill shows promise against Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for advanced cancers: first human trial launches
Disease control Recruiting nowThis study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 430 adults will take part. The drug is given through a vein, alone or with other treatments.
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC